Compare ORI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORI | DVA |
|---|---|---|
| Founded | 1923 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.9B |
| IPO Year | 1994 | 2003 |
| Metric | ORI | DVA |
|---|---|---|
| Price | $37.14 | $194.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $43.50 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.2M | 876.1K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 9.47% | N/A |
| EPS Growth | ★ 14.81 | N/A |
| EPS | 1.32 | ★ 2.87 |
| Revenue | $9,136,300,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $7.07 | $3.85 |
| Revenue Next Year | $6.86 | $3.07 |
| P/E Ratio | ★ $28.13 | $65.47 |
| Revenue Growth | ★ 10.99 | 6.46 |
| 52 Week Low | $35.60 | $101.00 |
| 52 Week High | $46.76 | $202.69 |
| Indicator | ORI | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 33.90 | 60.19 |
| Support Level | N/A | $191.57 |
| Resistance Level | $43.46 | $202.63 |
| Average True Range (ATR) | 0.73 | 5.17 |
| MACD | -0.22 | -2.21 |
| Stochastic Oscillator | 13.45 | 46.52 |
Old Republic International Corp is engaged in the business of insurance underwriting and related services. The company operates in two segments: Specialty Insurance and Title Insurance. The insurance provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others. The company generates the majority of its revenue from Specialty Insurance. The Specialty Insurance provides property and liability insurance principally to commercial clients.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.